What Are the Neurological Side Effects of Humira?

Humira (adalimumab) can cause rare but serious neurological side effects, the most concerning of which involve demyelination, a process in which the protective coating around nerve fibers breaks down. These events include conditions resembling multiple sclerosis, optic neuritis, transverse myelitis, and Guillain-Barré syndrome. The risk is low enough that most people on Humira will never experience a neurological problem, but the consequences when they do occur can range from temporary vision changes to lasting disability, which makes knowing the warning signs genuinely important.

Why Blocking TNF Can Affect the Nervous System

Humira works by neutralizing tumor necrosis factor-alpha (TNF-alpha), a signaling molecule that drives inflammation in conditions like rheumatoid arthritis, Crohn’s disease, and psoriasis. TNF-alpha is a legitimate target for those diseases, but it also plays a complicated role in the nervous system. Among other things, TNF-alpha helps maintain myelin, the insulating sheath that allows nerves to transmit signals efficiently. Block too much of it, and in certain individuals the immune system appears to turn on myelin itself.

This is the central irony of the neurological side effects: a drug designed to calm an overactive immune system can, in rare cases, provoke a different kind of immune attack, one directed at nervous tissue. The result is demyelination, which can occur in the brain, the spinal cord, the optic nerves, or the peripheral nerves in the limbs. That broad reach is why the neurological side effects of Humira look so varied on paper even though they share a common thread.

Demyelinating Lesions in the Brain and Spinal Cord

The most widely reported neurological complication is central nervous system demyelination, where patches of myelin loss show up on brain MRI scans and sometimes look indistinguishable from multiple sclerosis. These events are rare, with only a handful of published cases, but they have appeared across the different diseases Humira treats.

In one reported case, a patient with rheumatoid arthritis developed CNS demyelination a few months after starting adalimumab.¹ In another, a 45-year-old man being treated for Crohn’s disease developed multiple sclerosis-like demyelinating lesions seven months into treatment.² The pattern is consistent: patients who had no prior neurological symptoms develop new ones while on the drug, and brain imaging reveals lesions that were not there before.

Demyelination can also strike the spinal cord, a condition called transverse myelitis. A 40-year-old woman with Crohn’s disease on adalimumab developed acute leg weakness, sensory loss, and urinary problems; MRI showed a long lesion running down her cervical spinal cord along with a white matter lesion in the brain, ultimately leading to a diagnosis of relapsing-remitting multiple sclerosis.³ In a separate case, a 48-year-old man with rheumatoid arthritis developed a progressive myelopathy with sensory problems and difficulty walking after four years on adalimumab, with MRI showing a cervical cord lesion stretching from C2 to C7.⁴ That second case is a useful reminder that these events do not always appear in the first few months; they can emerge years into treatment.

Optic Neuritis

Optic neuritis, an inflammation of the nerve that connects the eye to the brain, is another recognized neurological complication. It typically presents as sudden blurring or loss of vision in one eye, often with pain behind the eye during movement. Among the early reports linking adalimumab to optic neuritis, researchers described what they believed were the first published cases of this specific association.⁵

A later review of the literature identified 21 cases of optic neuritis across all TNF inhibitors. Roughly a third of those patients who had MRI imaging showed evidence of demyelinating lesions elsewhere in the brain, suggesting the optic nerve inflammation was part of a broader process rather than an isolated event.⁶ This matters practically because a patient who develops optic neuritis on Humira should be evaluated for additional CNS involvement, not just treated for an eye problem.

Recovery from adalimumab-associated optic neuritis varies. In one case where the drug was stopped and the patient received high-dose intravenous steroids along with intravenous immunoglobulin, visual acuity improved only minimally, to the level of counting fingers.⁷ That outcome is sobering and underscores why early recognition matters: the longer inflammation goes unchecked, the harder it may be to reverse the damage.

Guillain-Barré Syndrome and Peripheral Nerve Damage

The neurological effects of Humira are not limited to the brain and spinal cord. Peripheral nerves, the ones running through your arms, legs, and face, can also be targeted. The most dramatic example is Guillain-Barré syndrome (GBS), an acute condition where the immune system attacks peripheral nerve myelin, leading to rapidly progressing weakness that can affect breathing muscles.

Several cases of GBS have been documented in patients on adalimumab. A patient being treated for psoriasis developed GBS as a late complication of treatment.⁸ A 71-year-old with Crohn’s disease developed GBS after just four injections.⁹ In a particularly complex case, a 31-year-old man with rheumatoid arthritis developed GBS confirmed by electromyography along with signs of meningeal involvement after his second adalimumab injection, demonstrating that both the central and peripheral nervous systems can be affected simultaneously.¹⁰

A slower-developing cousin of GBS called chronic inflammatory demyelinating polyneuropathy (CIDP) has also been reported. In one case, a patient on adalimumab developed bilateral facial nerve palsies, meaning both sides of the face became weak, as part of a CIDP picture. Symptoms gradually improved over months after adalimumab was stopped and the patient received immunoglobulin treatment along with oral steroids.¹¹

Who Faces Higher Risk

Because these events are so uncommon, researchers have not been able to run large trials to pin down exactly who is most vulnerable. The clearest risk factor identified so far is a personal or family history of multiple sclerosis or other demyelinating diseases. A case report of a 23-year-old man with autoimmune uveitis and a family history of MS describes how he developed two neurological attacks after starting adalimumab, with brain MRI revealing multiple new lesions. The authors explicitly warned physicians to be cautious when prescribing TNF blockers to patients with a family history of MS.¹²

A population-level study from Canada offered broader context. Among nearly 300,000 patients with rheumatic diseases, those exposed to TNF blockers had roughly double the rate of new MS diagnoses compared to unexposed patients.¹³ Doubling a very small risk still leaves the absolute numbers low, but it lends population-level weight to what case reports had been suggesting one patient at a time. Whether the drug triggers entirely new disease or unmasks something that was already developing beneath the surface remains an open question in the field.

People with autoimmune conditions already have an immune system that is primed to attack the body’s own tissues. Adding a TNF blocker can redirect that tendency toward nervous tissue in susceptible individuals. The challenge is that there is no reliable blood test or genetic marker to identify these individuals in advance.

What Happens When Humira Is Stopped

The encouraging news in most case reports is that stopping the drug leads to at least some improvement. One review of demyelinating events associated with TNF blockers found that prompt discontinuation was associated with favorable disease outcomes.¹⁴ In some cases, symptoms resolved completely without recurrence after the drug was withdrawn.¹⁵

But recovery is not guaranteed, and the degree of improvement varies. As mentioned above, at least one patient with optic neuritis was left with severely impaired vision despite aggressive treatment. Patients with transverse myelitis may have residual weakness or sensory changes. And in cases where the drug appears to have unmasked true relapsing-remitting multiple sclerosis, stopping Humira does not make the MS go away. It may halt further drug-driven inflammation, but the underlying disease process can continue on its own.

The speed of recognition matters. Patients and clinicians who catch new neurological symptoms early and stop the drug promptly tend to see better outcomes than those where the connection is made months after symptoms begin. This is complicated by the fact that early symptoms like mild tingling, a vague change in vision, or a new headache pattern are easy to dismiss.

How These Side Effects Are Managed

When a neurological side effect is suspected, stopping Humira is the first and most important step. Beyond that, treatment depends on the specific presentation. For demyelinating events affecting the brain or spinal cord, high-dose intravenous corticosteroids are the standard initial approach, the same treatment used for MS relapses. For GBS and CIDP, intravenous immunoglobulin (IVIg) is the usual first-line therapy.

There are reports of successful outcomes using IVIg even without discontinuing the TNF blocker. In one case, a patient with Crohn’s disease who developed GBS on adalimumab was treated with IVIg while continuing the drug and recovered.¹⁶ That approach goes against the usual recommendation and should not be considered standard practice, but it reflects the difficult real-world situation where a patient desperately needs their Crohn’s disease controlled and has limited alternative options.

If Humira is stopped because of a neurological side effect, the patient needs an alternative for the underlying condition. Switching to a different class of biologic, one that does not target TNF, is the standard strategy. Drugs that work through different mechanisms, such as those targeting interleukins or integrin receptors, are generally considered safer for patients who have experienced demyelinating events on a TNF blocker, though published evidence guiding these choices remains limited.

A Class-Wide Concern Across TNF Inhibitors

These neurological risks are not unique to Humira. All TNF inhibitors, including infliximab (Remicade), etanercept (Enbrel), certolizumab (Cimzia), and golimumab (Simponi), carry warnings about demyelinating events. An analysis of neurological events reported to the FDA’s adverse event system found that etanercept actually had the highest share of reports at about 42%, followed by infliximab at roughly 36%.¹⁷ These proportions partly reflect how many people use each drug, so they do not necessarily mean etanercept is more dangerous. But the data confirm that demyelination is a class effect tied to TNF suppression itself, not something specific to adalimumab’s structure.

One additional neurological concern worth mentioning relates to the broader immunosuppression that TNF blockers cause. In rare instances, patients on these drugs have developed progressive multifocal leukoencephalopathy (PML), a serious brain infection caused by reactivation of the JC virus. A case report described a patient on infliximab and methotrexate who developed PML alongside cryptococcal meningitis, both opportunistic infections that exploit a weakened immune system.¹⁸ While PML is more closely associated with other immunosuppressive drugs, it serves as a reminder that TNF blockers create a broader vulnerability to CNS infections on top of the demyelination risk.

Another rare but reported complication is vasculitis affecting nerve tissue. A report on juvenile stroke during long-term adalimumab therapy noted that vasculitis, inflammation of blood vessel walls, has been documented in patients on TNF blockers, including cases involving the peripheral nerves.¹⁹ Vasculitis-related nerve damage differs from demyelination mechanistically but can produce overlapping symptoms like weakness and numbness.

Neurological Side Effects in Children

Children on TNF blockers are not exempt from these risks. A study examining adverse event reports in pediatric inflammatory bowel disease patients treated with anti-TNF drugs between 2000 and 2018 identified 231 adverse events, of which 17 were neurological. The severe events included demyelinating neuropathy, optic neuritis, transverse myelitis, polyradiculoneuritis, sensorineural hearing loss, seizure, stroke, and a brain tumor. The median time from starting the drug to the neurological event was about six months. Among the 17 affected children, nine had complete resolution and eight had only partial recovery. The researchers estimated the rate of severe neurological adverse events in this population at roughly one case per 10,000 patient-years.²⁰

That incidence figure helps put the risk in perspective. If 10,000 children were each treated for one year, about one would be expected to develop a severe neurological complication. The number is small, but the consequences for that one child can be significant, particularly since nearly half of the severe pediatric cases in this dataset had only partial resolution. Pediatric gastroenterologists and rheumatologists are generally aware of these risks and weigh them against the substantial harm that uncontrolled inflammatory bowel disease or juvenile arthritis can cause.

Screening Before Starting Treatment

Given that the drug may unmask latent demyelinating disease, some researchers have raised the question of whether patients should undergo brain MRI before starting a TNF blocker. One case report explicitly suggested that performing brain MRI on asymptomatic patients before initiating anti-TNF therapy might be worthwhile to rule out pre-existing demyelinating disease.²¹ The idea has an intuitive appeal: if silent lesions are already present, putting that patient on a drug known to provoke demyelination seems unwise.

In practice, routine pre-treatment MRI is not standard care, largely because the neurological side effects are rare enough that screening every patient would generate many false alarms for every genuine finding. The cost-effectiveness calculation does not favor universal screening. However, the case for targeted screening is stronger. Patients with a family history of MS, those with unexplained neurological symptoms that were never fully evaluated, or those switching from one TNF blocker after developing suspicious symptoms on another, all arguably deserve at least a neurological exam and possibly imaging before starting or restarting a TNF inhibitor. The current state of the evidence has not produced formal screening guidelines, so the decision remains a judgment call between physician and patient. What the evidence does clearly support is vigilance during treatment: any new neurological symptom, from blurred vision to limb weakness to persistent tingling, warrants a prompt workup rather than a wait-and-see approach.